About
David is a Venture Partner with Catapult’s GM&C Life Sciences Fund, where he assesses investment opportunities and works with the Fund’s smaller investments to help companies successfully grow. David is a well-known consultant and non-executive director/Chairman who co-founded DxS Diagnostics in 2000 to exploit a personalised medicine technology he had invented while with AstraZeneca Diagnostics. DxS was sold to Qiagen in September 2009 for in excess of £100m. Prior to DxS, David was Head of Technology Development at AstraZenica Diagnostics for four years where he led a team of up to 15 scientists working on new genome technologies. David began his career as a Post-Doctoral Fellow with Warwick University Department of Biological Sciences, before joining Cambridge University Department of Medicine as a Senior Post-Doctoral Fellow where he researched the Genetics of Human Disease for six years. David holds a First Class BSc in Genetics from the University of York and PhD in Biochemist
Position in the VCSift Database
- • 2 investors at GM&C Life Sciences Fund are tracked.
- • 421 investors hold the Venture Partner role in VCSift. David Whitcombe is one of them.
- • 8,972 investors are based in London, England, United Kingdom.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- London, UK
Contact Information
Find more investors like David
Search Investors